Tscan Other Current Liab from 2010 to 2025

TCRX Stock  USD 1.91  0.14  6.83%   
Tscan Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Tscan Therapeutics Other Current Liabilities regression line of annual values had r-squared of  0.65 and arithmetic mean of  2,925,373. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
12.3 M
Current Value
12.9 M
Quarterly Volatility
4.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 2.9 M, Interest Income of 7.6 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 19.85, Dividend Yield of 0.0 or PTB Ratio of 2.4. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tscan Therapeutics Correlation against competitors.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Latest Tscan Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Tscan Therapeutics over the last few years. It is Tscan Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tscan Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Tscan Other Current Liab Regression Statistics

Arithmetic Mean2,925,373
Geometric Mean228,088
Coefficient Of Variation162.05
Mean Deviation3,671,888
Median31,000
Standard Deviation4,740,469
Sample Variance22.5T
Range12.9M
R-Value0.81
Mean Square Error8.5T
R-Squared0.65
Significance0.0002
Slope801,851
Total Sum of Squares337.1T

Tscan Other Current Liab History

202512.9 M
202412.3 M
202310.7 M
20223.2 M
20214.9 M
20202.5 M

About Tscan Therapeutics Financial Statements

Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities12.3 M12.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.